肝癌患者血清和腹水可溶性肿瘤坏死因子受体—p55的测定

OBJECTIVE: To examine soluble tumor necrosis factor receptor-p55 (sTNFR-p55) levels in the serum and ascitic fluid and investigate the significance of this examination in assessment of the clinical status of patients with primary hepatocellular carcinoma (HCC). METHODS: Enzyme-linked immunosorbent assay (ELISA) was used to examine sTNFR-p55 levels in the serum and ascitic fluid in 25 patients with HCC and 25 with liver cirrhosis (LC). RESULTS: sTNFR-p55 levels in the serum and ascitic fluid in patients with HCC were significantly higher than those in patients with LC and controls (P=0.001). No significant difference was found between LC and the control in terms of serum sTNFR-p55 levels (P=0.19). Positive correlation was observed between sTNFR-p55 levels in the serum and in ascitic fluid of patients with HCC and LC (r=1.000, P<0.001). Logistic regression revealed that in patients with HCC, serum sTNFR-p55 levels were positively correlated with TBil and AFP in the peripheral blood (r=0.524, P=0.01 and r=0.234, P=0.03, respectively). CONCLUSIONS: Increased sTNFRs-p55 levels in the serum and ascitic fluid reflect abnormal immune status of the patients with HCC and help predict the development of tumor.     

肝癌患者血浆肿瘤坏死因子及其可溶性受体Ⅰ的意义

目的：探讨肝癌患者血浆TNF和sTNFR-I的临床意义。方法：分别用放射免疫法和ELISA法检测36例肝癌患者血浆TNF和sTNFR-I。结果：肝癌患者血浆TNF、sTNFR-I均显著高于肝硬变和正常人。sTNFR-I水平与AFP、TB、g-GT、ALP无产，与血清白蛋白水平呈负相关。Ⅲ、Ⅳ期或门脉癌栓患者sTNFR-I高于Ⅱ期或门脉无癌栓患者，TNF与分期及门脉癌栓无关；有效治疗后sTNFR-I水平明降低。结论：sTNFR-I可能参与了肿瘤细胞的免疫逃避机制。检测sTNFR-I有助于解肝癌患者的免疫状态、病程分期、判断预后、监测治疗，临床价值优于TNF测定。     

银屑病患者血清可溶性肿瘤坏死因子受体水平的检测

银屑病患者血清可溶性肿瘤坏死因子受体水平的检测张开明刘梅青尹兴平杨小英由于肿瘤坏死因子（ＴＮＦ）α在银屑病发病中具有重要的作用［１，２］，故推测可溶性ＴＮＦ受体（ｓＴＮＦＲ）在银屑病发病中可能也有一定的意义。为此，我们检测了银屑病患者血清中ｓＴＮＦＲ...     

可溶性肿瘤坏死因子受体与肿瘤

可溶性肿瘤坏死因子受体(SolubleTumorNecrosisFactorRecptor,sTNFR)有和两种类型,分别来自膜TNFR(55KD)-sTNFR和膜TN-FR(75KD)-sTNFR。许多细胞可以产生sTNFR,如中性粒细胞、单核细胞、成纤维细胞等,能表达TNFR的细胞均能产生sTNFR[1]。Higuchi的实验证明,sTNFR是细胞表面TNFR的膜外区域(胞外段)在蛋白酶作用下,裂解脱落形成的[2]。1990年schall[3]从癌症血清中纯化获得sTNFR(TNF-BP)。sTNFR能够与TNF结合,从而影响TNF的功能,因此sTNFR在体内具有重要的生物学意义。sTNFR少量存在于正常人的血、尿液中。在…     

食道癌患者血清可溶性肿瘤坏死因子受体1测定及临床意义

目的 探讨食管癌患者的异常免疫状态下血清sTNFR1检测的临床意义。材料和方法 用双单抗夹心酶联免疫吸附法（ELISA）检测40例食管癌患者和30例正常人血清sTNFR1水平。结果 食管癌病人血清sTNFR1浓度[（129.45±42.54）U/ml]显著高于正常人[（51.64±26.67 U/ml）,P<0.05],且其升高程度与病变食管长度、病情轻重及有无恶液质有关。结论 sTNFR1的检测对食道癌的早期诊断和预后具有实用价值。     

肿瘤坏死因子受体-p55在大肠癌中的表达及其意义

目的探讨大肠癌组织中肿瘤坏死因子受体（Ｔｕｍｏｒ ｎｅｃｒｏｓｉｓ ｆａｃｔｏｒ ｒｅｃｅｐｔｏｒ－ｐ５５, ＴＮＦＲ－Ｐ５５）表达的数目与临床病 理因素及肿瘤分期间的关系。方法用免疫组织化学ＳＡＢＣ法检测９１例大肠癌组织、８１例癌旁组织及１３例正常肠粘 膜标本中 ＴＮＦＲ－ｐ５５的表达。结果大肠癌组织中 ＴＮＦＲ－ｐ５５表达比癌旁组织及正常组织显著增高,癌旁组织 ＴＮＦＲ－ｐ５５ 表达亦显著高于正常组织。在大肠癌组织中,ＴＮＦＲ－ｐ５５表达与浆膜浸润程度和淋巴结转移与否呈负相关,即肿瘤侵及 浆膜或有淋巴结转移时 ＴＮＦＲ－ｐ５５表达低。同时,Ｄｕｋｅｓ Ａ期和 Ｂ期患者 ＴＮＦＲ－ｐ５５表达显著高于 Ｄｕｋｅｓ Ｃ期。结论 检测ＴＮＦＲ－ｐ５５的表达对判断大肠癌恶性程度,预测肿瘤浸润深度、淋巴结转移趋势及肿瘤分期有重要价值。     

Increased serum and ascitic fluid levels of soluble tumor necrosis factor-p55 in hepatocellular carcinoma patients

Objective: To explore the levels of serum and ascitic fluid soluble tumor necrosis factor receptor-p55 (sTNFR-p55) and understand their clinical implication in primary hepatocellular carcinoma (HCC) patients. Methods: Enzyme-linked immunosorbent assay (ELISA) was used to examine the levels of sTNFR-p55 in the serum and ascitic fluid in 25 HCC patients and 25 patients with liver cirrhosis (LC). The test was also performed on the serum of 30 healthy subjects who served as control group. To assess the clinical effects of increased serum concentrations of sTNFR-p55, four parameters were analyzed by logistic regression. Results: Serum and ascitic fluid levels of sTNFR-p55 in HCC patients were significantly higher than those in LC patients and controls (P=0. 001). No significant difference was found between serum sTNFR-p55 levels in the latter 2 groups (P = 0. 19), and positive correlation between serum levels of sTNFR-p55 and that in ascitic fluid was noted in the 2 patient groups (r=1. 000, P<0. 001). Level     

肝细胞癌患者血清可溶性Fas水平检测及其意义

目的:探讨肝细胞癌(HCC)息者血清可溶性Fas(sFas)受体与肝细胞癌之间的关系.方法:用双抗夹心ELISA法,检测45例HCC、30例肝硬化(LC)患者血清sFas水平.结果:HCC血清sFas浓度为16.5±3.1ng/L,明显高于LC 8.4±2.5 ng/L和正常对照组3.1±1.1ng/L(P＜0.01).结论:肝细胞癌患者血清中高水平的sFas受体,竞争性地与Fas受体的天然配体FasL(Fas Ligand)结合而抑制肝癌细胞凋亡,这可能是肝癌细胞逃避机体免疫监视得以生存和转移的重要机制之一.     

消化道恶性肿瘤患者血清可溶性肿瘤坏死因子受体-Ⅰ的检测及其临床评价

目的 :了解可溶性肿瘤坏死因子受体 -Ⅰ (sTNFR -Ⅰ )在消化道恶性肿瘤患者中的临床意义。方法 :应用双抗体夹心ELISA法 ,对 37例食管癌、4 1例胃癌、30例大肠癌患者血清sTNFR -Ⅰ水平进行了检测。结果 :三组肿瘤患者血清sTNFR -Ⅰ水平显著高于对照组 ,且随肿瘤临床病理分期增加而增高 ,有转移者 ,显著高于无转移者。手术切除肿瘤后sTNFR -Ⅰ水平下降 ,肿瘤复发时 ,sTNFR -Ⅰ水平上升。结论 :检测血清sTNFR -Ⅰ水平有助于消化道恶性肿瘤患者的诊断及预后判断。     

肺癌患者血清肿瘤坏死因子受体检测及其应用价值

目的　评价血清可溶性肿瘤坏死因子受体Ⅰ (STNFR -Ⅰ )检测的临床应用价值。方法　采用酶联免疫吸附法 (ELISA)对 6 2例肺癌患者及 6 1例健康人进行了STNFR -Ⅰ的测定。结果　肺癌组STNFR -Ⅰ值为 2 .84± 1.8ng/ml,高于健康对照组 0 .93± 0 .2 9ng/ml,两组比较P <0 .0 1,且STNFR -Ⅰ水平随肺癌病期进展而升高 ,Ⅰ、Ⅱ、Ⅲ、Ⅳ期分别为 2 .2 3± 0 .47μg/L、2 .34± 0 .6 8μg/L、2 .6 3±0 .6 7ng/ml、3.5 1± 1.6 2 μg/L。肺癌患者STNFR -Ⅰ阳性率 (80 .7% )超过了血清癌胚抗原 (CEA)的阳性率 (38.7% )。结论　测定血清中STNFR -Ⅰ对肺癌的诊断、分期和预后均有较为实用的临床应用价值。     

风湿热患儿血清可溶性肿瘤坏死因子受体I的变化

目的 :了解肿瘤坏死因子系统在急性风湿热 (ARF)中的作用。方法 :用ELISA法对ARF、风湿性心脏病风湿活跃期 (活动期组 ) ,风湿性心脏病风湿静止期 (静止期组 )及健康人对照组血清可溶性肿瘤坏死因子受体I(sTN FRI)水平进行检测 ,并与血沉 (ESR) ,C反应蛋白 (CRP)进行相关分析。结果 :活动期组血清sTNFRI浓度为 (3 92±1 2 8)ng·ml- 1 明显高于静止期组 (1 43± 0 6 6 )ng·ml- 1 及健康人对照组 (1 0 6± 0 42 )ng·ml- 1 (均 P<0 .0 1 ) ;静止期组与健康人对照组比较 ,差异无显著性 (P >0 .0 5 )。活动期组血清sTNFRI改变与CRP呈正相关 (r =0 82 4 ,P <0 .0 0 1 )。结论 :ARF患儿血清sTNFRI水平可作为判断风湿活跃的一项实验室指标。     

肝炎患者血清TNF浓度的测定及临床意义

目的探讨肿瘤坏死因子（TNF）与肝损伤的关系。方法测定NS例肝炎患者的TNF浓度及肝功能,同时以30名健康献血员作对照组,结果以t检验作统计学分抓结果各组肝病患者血清TNF水平较正常对照组（0.74±0.15ng·ml-1）显著升高（P＜0.01）,以重症肝炎（1.58±0.67ng·ml-1）并高最显著（P＜0.001）。结论TNF在重症肝炎发病中起重要作用,是参与肝损伤及坏死的重要介质因子。     

食管癌患者血清可溶性肿瘤坏死因子受体水平及临床意义

目的　探讨食管癌患者的血清可溶性肿瘤坏死因子受体 (sTNF RI、sTNF RII)水平及其临床意义。方法　采用双抗体夹心酶联免疫吸附法检测 5 6例食管癌患者和 2 0例正常人血清sTNF RI、sTNF RII及癌胚抗原(CEA)水平。结果　食管癌患者的血清sTNF RI显著高于健康对照组 (P <0 0 0 1) ,而sTNF RII则明显低于健康对照组 (P <0 0 5 ) ,sTNF RII与sTNF RI的比值明显低于健康对照组 (P <0 0 0 1)。血清sTNF RII变化的敏感性明显高于血清CEA。结论　血清sTNF RI和sTNF RII水平检测在食管癌的辅助诊断具有一定的临床应用价值。     

正常妊娠与妊娠高血压综合征孕妇胎盘中肿瘤坏死因子α及其受体的变化

目的：探讨肿瘤坏死因子α（TNF-α）及其p55型受体（p55 TNFR）在正常妊娠及妊娠高血压综合征（妊高征）发病机制中的作用。方法：采用免疫组化法研究12例正常妊娠妇女、43例妊高征患者胎盘中胎儿面和母体面TNF-α和p55 TNFR的表达。结果：正常妊娠组与妊高征组胎盘中均可见TNF-α和p55 TNFR的表达,中、重度妊高征组表达强度较正常妊娠组与轻度妊高征组显著增加（P<0.05）,中、重度妊高征组母体 面的表达强度显著高于胎儿面（P<0.01）。 结论：正常妊娠妇女胎盘中表达少量的TNF-α和p55 TNFR,参与正常妊娠的调节。胎盘中异常增加的TNF-α与p55 TNFR可能在妊高征的发病中起重要的作用。